Learn more

SIGNATURE DIAGNOSTICS AG

Overview
  • Total Patents
    22
  • GoodIP Patent Rank
    217,447
About

SIGNATURE DIAGNOSTICS AG has a total of 22 patent applications. Its first patent ever was published in 2006. It filed its patents most often in EPO (European Patent Office), Canada and Germany. Its main competitors in its focus markets biotechnology and computer technology are ZORAGEN BIOTECHNOLOGIES LLP, GENESUPPORT SA and SHENZHEN BGI RES INST.

Patent filings in countries

World map showing SIGNATURE DIAGNOSTICS AGs patent filings in countries

Patent filings per year

Chart showing SIGNATURE DIAGNOSTICS AGs patent filings per year from 1900 to 2020

Focus industries

Focus technologies

Top inventors

# Name Total Patents
#1 Mayr Tobias 18
#2 Adams Hans-Peter 17
#3 Hinzmann Bernd 16
#4 Rosenthal Andre 11
#5 Clevert Djoerk-Arne 5
#6 Rujan Tamas 4
#7 Model Fabian 4
#8 Rosenthal André 2
#9 Clevert Djörk-Arné 2
#10 Pechanska Paulina 1

Latest patents

Publication Filing date Title
EP2759605A1 A method for predicting a manifestation of an outcome measure of a cancer patient
US2014342925A1 Method for predicting a manifestation of an outcome measure of a cancer patient
EP2524968A1 Methods and kits for diagnosing colorectal cancer
EP2524967A1 Methods and kits for diagnosing colorectal cancer
EP2508619A1 Method and kits for the prediction of response/nonresponse to the treatment with an anti-EGFR antibody in patients with colorectal cancer of all UICC stages
WO2011051414A1 Method for the prognosis of ovarian carcinoma
EP2388336A1 Method and kits for diagnosing colorectal cancer
EP2304057A2 Method for the detection of ovarian cancer
DE102006035393A1 Prognostic markers for the classification of the three-year progression-free survival of patients with colon carcinoma based on expression profiles of biological samples
DE102006035392A1 Prognostic markers for the prediction of five-year progression-free survival of patients with colon carcinoma based on expression profiles of biological samples
DE102006035388A1 Prognostic markers for the classification of colon carcinomas based on expression profiles of biological samples